echocardiographic estimation of pulmonary artery pressure and other echocarciographic and clinical features in 175 consecutive adult SSD patients (74 male, 101 female, mean age = 37 ± 11 years) recruited from a local hospital and community clinics who were followed for a median period of 12 months. Methods: PH was prospectively defined as a tricuspid regurgitation jet velocity of > 2.5 m/ sec. 2-Dimensional assessment of chamber dimensions and ventricular systolic performance, pulsed Doppler quantitation of left ventricular stroke volume, continuous wave Doppler estimation of pulmonary artery systolic pressure, and right ventricular systolic and diastolic function (dP/dt from TR spectral trace) were examined. Results. PH was present in 33 % of patients and peak TR velocities (TRV) > 3 m/sec were observed in 9%. In univariate analysis, TRV was the strongest predictor of all-cause mortality (relative risk 8.3; 95% CI = 1.7 to 40; P = 0.003). TRV did not correlate with left ventricular ejection fraction, stroke volume or cardiac output. Patients with TRV > 2.5 m/ sec had significantly larger right atrial areas (20 ± 5 vs 18± 4 cm 2 , P < 0.001, values are mean + SD) and evidence of right ventricular systolic and diastolic dysfunction (+dP/dt; 419 ± 139 vs 659 ± 371 mmHg/sec, P < 0.01 and -dP/dt; 157 ± 52 vs 236 ± 77 mmHg/ sec, P < 0.001). Ventricular volumes, ejection fraction, and severity of mitral regurgitation were similar between groups as were non-echo SSD parameters including fetal hemoglobin, white blood cell and platelet counts, and hydroxyurea use. Conclusion: Secondary pulmonary hypertension is a powerful independent predictor of mortality in SSD, is unrelated to cardiac output and is associated with abnormalities in RV systolic and diastolic function. Echocardiography can be used as a screening tool to identify a high risk subgroup in SSD that may benefit from therapeutic interventions.
Purpose:
We sought to determine the cost-effectiveness of screening coronary artery disease (CAD) patients with B-type natriuretic peptide (BNP) to identify those with low left ventricular ejection fraction (EF). Methods: We constructed a decision tree that compared screening with BNP with followup echocardiography (echo) in those with a high BNP to no screening. We estimated economic and health outcomes using a Markov-model based on data from the SOLVD treatment and prevention trials. We determined the sensitivity (67%) and specificity (78%) of BNP (Biosite, threshold 100 pg/ml) for the detection of an EF < 40% using data from 293 patients with coronary artery disease and no history of heart failure. Results: The population for the base case had mean age of 69 years and 92% were male. The prevalence of EF below 40% was 3.1%. Screening 1000 CAD patients with BNP followed by echo in those with a BNP > 100 pg/dl increased the cost of care by $216,000, and improved outcome by 7.2 quality adjusted life years ($30,000/QALY). Screening with echo in all patients provided greater outcome compared to first testing with BNP (3.3 QALYs) but cost an additional $445,000 ($135,000/QALY). The cost-effectiveness of screening was most sensitive to the prevalence of low ejection fraction (Figure) . If the prevalence is over 1.5%, screening increases outcome at a cost less than $50,000/QALY gained. Conclusion: Screening men with CAD for low EF with BNP improves outcome at a cost that is less than other accepted medical treatments.
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Healthcare observed. In a risk-adjusted Cox model (adjusted for risk factors and symptoms), annual death or MI rates were 0.9% for women with <50% stenosis versus (vs) 2.3%-6.0% for those with 1-3 vessel CAD (p=0.001). Angina hospitalization rates were 14% and 25% for women with < vs >50% stenosis (p=0.03). After yr 1, repeat Angio or angina hospitalization was 1.8-fold higher in women with <50% stenosis vs 1 vessel CAD women (p<0.0001). 4-yr mean±standard deviation costs (x $1,000) ranged from $13±$16 to $27±$25 for 0 to 3 vessel CAD (p<0.0001). Due to a younger age at Angio, lifetime costs were $206,246 for women with <50% stenosis increasing to $540,136 for those with 3 vessel CAD (Figure) .
In conclusion, symptom-driven care for women is costly even in the absence of obstructive CAD. The purpose of this pilot study was to examine the use of simulation as a tool for teaching coronary angiography and angioplasty techniques to Fellows in the Peoples Republic of China. Methods: The angiography and angioplasty simulator was designed and developed using a systematic approach. First, a detailed description of 10 different clinical cases were developed and reviewed for content and accuracy by several experienced Interventional Cardiologists. Each Procedure Description was then broken down into the finite constituent tasks a Cardiologist must perform in order to successfully perform angiography and angioplasty. The tasks were then analyzed to ascertain their performance domain (cognitive, psychomotor) with particular emphasis on those aspects of performance which are prone to error. This Task Analysis was then reviewed by Interventional Cardiologists, revised, and became the metric for the development of the simulator. In November 2002, six simulators were used as part of a 5 day seminar for 23 Cardiology Fellows in Beijing, and again in February 2003. Experienced Cardiologists from the United States and China served as faculty. The seminars consisted of didactic lectures followed by practice and feedback sessions on the simulators. At the end of each day student progress and performance was reviewed by Faculty. In addition, the candidates completed seminar evaluation forms.
Results:
The faculty members felt that the simulation content was valid, in that it sufficiently replicated interventional procedures to provide useful and valuable training. Subjectively, the system was able to quickly discriminate between master and novice performers. Candidates demonstrated substantial improvement in the performance of targeted tasks, particularly in the areas of refining angiographic views and interventional tool manipulation.
Conclusion: This pilot study demonstrated that simulation, when properly designed and integrated into a curriculum, is accepted by Cardiologists as a training tool, and that it has the propensity to markedly improve the performance of Fellows. Follow-on formal studies are planned to document concurrent and predictive validity.
